Another study showed that serum MCP-1 concentrations in RA patients reflected their disease activity [42] and that treatment with a MCP-1 antagonist prevented arthritis in a preclinical mouse model [43]. This evidence concerns the gene CCL2 and rheumatoid arthritis.